Minerva Neurosciences | NERV - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Adma Biologics USD 76.41M 6.8M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Takeda JPY 1.02T 400.98B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09